Advertisement
Advertisement
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
4.06
USDSponsored
0.00
0.00%
May 13, 15:59 UTC -4
Closed
Pre-Market
4.07
+0.01
+0.12%
OBIO Earnings Reports
Positive Surprise Ratio
OBIO beat 10 of 12 last estimates.
83%
Next Report
Next Week
Date of Next Report
May 18, 2026
Estimate for Q1 26 (Revenue/ EPS)
$194.56K
/-$0.43
Implied change from Q4 25 (Revenue/ EPS)
-99.37%
/+230.77%
Implied change from Q1 25 (Revenue/ EPS)
-77.58%
/-12.24%
Orchestra BioMed Holdings, Inc. Ordinary Shares earnings per share and revenue
On Mar 12, 2026, OBIO reported earnings of -0.13 USD per share (EPS) for Q4 25, beating the estimate of -0.38 USD, resulting in a 66.33% surprise. Revenue reached 30.92 million, compared to an expected 943.20 thousand, with a 3177.87% difference. The market reacted with a -4.78% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.43 USD, with revenue projected to reach 194.56 thousand USD, implying an increase of 230.77% EPS, and decrease of -99.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Orchestra BioMed Holdings, Inc. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Orchestra BioMed Holdings, Inc. Ordinary Shares reported EPS of -$0.13, beating estimates by 66.33%, and revenue of $30.92M, 3177.87% above expectations.
How did the market react to Orchestra BioMed Holdings, Inc. Ordinary Shares's Q4 2025 earnings?
The stock price moved down -4.78%, changed from $4.60 before the earnings release to $4.38 the day after.
When is Orchestra BioMed Holdings, Inc. Ordinary Shares expected to report next?
The next earning report is scheduled for May 18, 2026.
What are the forecasts for Orchestra BioMed Holdings, Inc. Ordinary Shares's next earnings report?
Based on --
analysts, Orchestra BioMed Holdings, Inc. Ordinary Shares is expected to report EPS of -$0.43 and revenue of $194.56K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement